Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

Title of the item:

Computational Screening of Plant-Derived Natural Products against SARS-CoV-2 Variants.

Title:
Computational Screening of Plant-Derived Natural Products against SARS-CoV-2 Variants.
Authors:
Ansari, Waseem Ahmad
Khan, Mohd Aamish
Rizvi, Fahmina
Ali, Kajim
Hussain, Mohd Kamil
Saquib, Mohammad
Khan, Mohammad Faheem
Subject Terms:
SARS-CoV-2
CORONAVIRUS spike protein
EPIGALLOCATECHIN gallate
HESPERIDIN
CARCINOGENICITY
Source:
Future Pharmacology; Dec2022, Vol. 2 Issue 4, p558-578, 21p
Academic Journal
The present study explores the efficacy of plant-derived natural products (PDNPs) against spike glycoproteins (S-glycoprotein) of SARS-CoV-2 variants using molecular docking, ADMET, molecular dynamics (MD) simulation and density-functional theory (DFT) analysis. In all, 100 PDNPs were screened against spike glycoprotein of SARS-CoV-2 variants, namely alpha (B.1.1.17), beta (B.1.351), delta (B.1.617), gamma (P.1) and omicron (B.1.1.529). Results showed that rutin, EGCG, hesperidin, withanolide G, rosmarinic acid, diosmetin, myricetin, epicatechin and quercetin were the top hit compounds against each of the SARS-CoV-2 variants. The most active compounds, rutin, hesperidin, EGCG and rosmarinic acid gave binding scores of −10.2, −8.1, −8.9, −8.3 and −9.2 kcal/mol, against omicron, delta, alpha, beta and gamma variants, respectively. Further, the stability of docked complexes was confirmed by the analysis of molecular descriptors (RMSD, RMSF, SASA, Rg and H-bonds) in molecular dynamic simulation analysis. Moreover, the physiochemical properties and drug-likeness of the tested compounds showed that they have no toxicity or carcinogenicity and may be used as druggable targets. In addition, the DFT study revealed the higher activity of the tested compounds against the target proteins. This led us to conclude that rutin, hesperidin, EGCG and rosmarinic acid are good candidates to target the S-glycoproteins of SARS-CoV-2 variants. Further, in vivo and clinical studies needed to develop them as drug leads against existing or new SARS-CoV-2 variants are currently underway in our laboratory. [ABSTRACT FROM AUTHOR]
Copyright of Future Pharmacology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Please log in to access the full text.

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.